Study design and setting
MSSA bacteremia
MAY
We performed an open-label, phase III–IV superiority randomized clinical trial of patients with MSSA bacteremia at 19 Spanish university hospitals (the SAFO trial). Participants were recruited from May 2019 to February 2022. Before inclusion in the trial, all patients or legal representatives provided written informed consent. All participants were able to withdraw from the study at any time without further explanation. The study was authorized by the Spanish Medicines and Healthcare Products Regulatory Agency (AEMPS; 18-0905) and by the Bellvitge University Hospital Ethics Committee (AC069/18). The protocol has been published elsewhere